Restoring Dystrophin Expression in Duchenne Muscular Dystrophy: A Phase I/II Clinical Trial Using AVI-4658

Update Il y a 5 ans
Reference: EUCTR2006-003833-33

  • | Country :
  • -
  • | organs :
  • -
  • | Specialty :
  • -

Extract

The purpose of this trial is to evaluate the safety and tolerability of a single intramuscular (IM) dose of AVI-4658, a phosphorodiamidate Morpholino oligomer (PMO) at increasing dosages compared to placebo in up to 9 DMD subjects divided into three groups.


Inclusion criteria

  • Duchenne Muscular Dystrophy

Links